Skip to main content
Premium Trial:

Request an Annual Quote

Linus Biotechnology Raises $16M in Series A Funding

NEW YORK – Linus Biotechnology announced Thursday that it raised over $16 million in Series A funding, which it will use to advance its StrandDx platform for correlating genomics and environmental exposures to biological responses.

GreatPoint Ventures and Bow Capital led the funding round. Other investors included Divergent Investments, the David Bellet Family Office, and Gillian Sandler, as well as Nicole Shanahan, the president of Bia-Echo Foundation; and Sanford Robertson, the cofounder of Francisco Partners and former board member of Salesforce; and others.

The StrandDx platform analyzes hair samples for markers of environmental exposures related to complex disorders such as autism spectrum disorders (ASD), amyotrophic lateral sclerosis, psychosis, schizophrenia, and inflammatory bowel disease. LinusBio has stated that it will initially focus on neurological disorders.

The Icahn School of Medicine at Mount Sinai spinout last year announced plans to launch its ASD assay, StrandDx-ASD, which aims to speed up ASD diagnoses by analyzing hair samples from people as young as newborns.

StrandDx-ASD has received breakthrough device designation from the US Food and Drug Administration and CE marking in the European Union.

The current funding will contribute to growing LinusBio's workforce in addition to further developing the StrandDx platform.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.